ACM
ADMA icon

Ashford Capital Management’s ADMA Biologics ADMA Stock Holding History

Ashford Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82M Sell
337,220
-24,280
-7% -$221K 0.3% 59
2026
Q1 		$3.26M Buy
+361,500
New +$5.7M 0.4% 56

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ashford Capital Management's ADMA Position: Q2 2026 in Review

Ashford Capital Management reduced its ADMA Biologics (ADMA) stake by 6.7% in Q2 2026, selling an estimated $221K and leaving 337,220 shares worth $2.82M. The position accounts for 0.3% of the portfolio, ranked #59.

Ashford Capital Management first reported a position in ADMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.26M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Ashford Capital Management held 337,220 shares of ADMA Biologics worth $2.82M as of Q2 2026.
  • Ashford Capital Management sold 24,280 ADMA Biologics shares in Q2 2026, an estimated $221K.
  • ADMA Biologics made up 0.3% of Ashford Capital Management's portfolio in Q2 2026, its #59 holding.
  • Ashford Capital Management first reported a position in ADMA Biologics in Q1 2026 and has held it in 2 quarters since.
  • Ashford Capital Management's ADMA Biologics position peaked at $3.26M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Ashford Capital Management's 13F filing for Q2 2026, filed 21 Aug 2026.